National trends in the usage and success of sacral nerve test stimulation.
OBJECTIVE
Little is known about outcomes of sacral neuromodulation in the general community, with published reports to date limited to case series or randomized, controlled trials. The goal of this analysis was to identify the national sacral neuromodulation test phase success rate and patient factors that contribute to success.


METHODS
Medical claims data were obtained from a 5% sample of Medicare beneficiaries (1997 to 2007) and from employees of 25 large (Fortune 500) companies (Ingenix®, 2002 to 2007). Using billing codes for the sacral neuromodulation procedure, success was defined as progressing from test phase (percutaneous or staged) to battery implantation. The rate of success was compared based on age, race, gender and diagnosis.


RESULTS
In the Medicare sample 358 patients received percutaneous test stimulation and 1,132 underwent 2-stage lead placement, of whom 45.8% and 35.4%, respectively, underwent subsequent battery implantation. In the privately insured sample there were 266 percutaneous procedures and 794, 2-stage procedures. Percutaneous procedures were followed by battery placement in 24.1% of cases, whereas 50.9% of staged procedures resulted in battery implantation. Gender was the only consistent predictor of success, with female patients demonstrating higher success rates in each data set.


CONCLUSIONS
The sacral neuromodulation success rates in these data sets are inferior to those published in case series and small randomized, controlled trials. Women had significantly better results than men and privately insured individuals had better results than those with Medicare, indicating a potential age effect.
Department of Urology, University of Michigan, Ann Arbor, Michigan 48109-5330, USA. annepell@med.umich.edu
Anne P
AP
Cameron
Jennifer T
JT
Anger
Rodger
R
Madison
Christopher S
CS
Saigal
J Quentin
JQ
Clemens
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D058542:Implantable Neurostimulators / Q000706:statistics & numerical data* / Q000639:trends; D008160:Lumbosacral Plexus; D008297:Male; D012074:Remission Induction; D014555:Urination Disorders / Q000601:surgery*
Urology. 2005 Oct;66(4):746-50
16230129
Neurourol Urodyn. 2007;26(1):19-28; discussion 36
17078071
J Urol. 2006 Mar;175(3 Pt 1):835-41
16469561
Int Urogynecol J Pelvic Floor Dysfunct. 2003 Nov;14(5):305-8; discussion 308-9
14618305
Eur Urol. 2007 May;51(5):1357-63
17113216
Am J Obstet Gynecol. 2002 Dec;187(6):1462-5; discussion 1465
12501047
J Urol. 2009 Oct;182(4):1449-52
19683295
J Urol. 1999 Aug;162(2):352-7
10411037
Urology. 2009 Apr;73(4):731-5
19193415
Neurourol Urodyn. 2010;29 Suppl 1:S18-23
20419795
World J Urol. 2008 Dec;26(6):623-6
18629503
Int Urogynecol J Pelvic Floor Dysfunct. 2003 Oct;14(4):223-8; discussion 228
14530831
J Urol. 2007 Jul;178(1):197-9; discussion 199
17499773
J Urol. 2007 Nov;178(5):2029-34
17869298
Scand J Urol Nephrol Suppl. 2002;(210):87-95
12475023
J Urol. 2001 Jan;165(1):15-9
11125353
Am J Obstet Gynecol. 2007 Jul;197(1):96.e1-5
17618775
Obstet Gynecol. 2007 Mar;109(3):707-14
17329524